Farrer Park Hospital Introduces High Intensity Focused Ultrasound (HIFU) Treatment for Uterine Fibroid in Singapore

SINGAPORE, Nov. 5, 2019 /PRNewswire/ -- Farrer Park Hosiptal (FPH) introduces High Intensity Focused Ultrasound (HIFU) inSingapore. HIFU is a new technology for the treatment of uterine fibroids, adenomyoma, adenomyosis. It is a non-invasive surgery that uses focused ultrasound to generate hig...

2019-11-05 09:00 334

Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830

INCHEON, South Korea, Nov. 4, 2019 /PRNewswire/ -- Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis....

2019-11-05 08:22 329

Health Charities Benefit from Nationwide Fundraising Campaign

SYDNEY, Nov. 5, 2019 /PRNewswire/ -- AFT Pharmaceuticals is getting behind three charities in a bid to help them raise vital funding for vulnerable Aussies - and get people talking about health. The company's founder and CEO, Hartley Atkinson says the initiative is an opportunity to give back to...

2019-11-05 05:30 451

Mum Hails $10 Childs Farm Skincare Products "Life-changing" After They Clear Her Daughter's Severe Eczema

"As a parent it's so frustrating not to be able to help your child when they're in need. I just felt so useless." BRISBANE, Australia, Nov. 5, 2019 /PRNewswire/ -- Tamika Hayley from Brisbane , says using theChilds Farm skincare range

2019-11-05 03:00 439

Luye Pharma's LY03004 Manufacturing Facility Successfully Passes U.S. FDA Pre-approval Inspection with Zero Observation

SHANGHAI, Nov. 4, 2019 /PRNewswire/ -- LY03004, Luye Pharma's innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market. The company has announced that it has received the Establishment Inspection Report from the U.S....

2019-11-05 00:39 376

Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®

- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine INGELHEIM, Germany, and INDIANAPOLIS,...

2019-11-04 22:00 2884

China Biologic Products to Report Third Quarter 2019 Financial Results

BEIJING, Nov. 4, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2019 financial results o...

2019-11-04 21:30 6068

Seoul National University Bundang Hospital Achieves Global Healthcare Accreditation

PALM BEACH GARDENS, Florida, Nov. 4, 2019 /PRNewswire/ -- Seoul National University Bundang Hospital (SNUBH) ( in Seoul, South Korea has been awarded a three-year term of accreditation by the Global Healthcare Accreditation (GHA) Program ( http://globalhealthcareaccre...

2019-11-04 21:00 454

Ossur and Alfred Mann Foundation Sign New Agreement to Extend Exploration of Mind-Controlled Prosthetics

REYKJAVIK, Iceland and SANTA CLARITA, CA, Nov. 4, 2019 /PRNewswire/ -- Jon Sigurdsson, President & CEO of Ossur and John Petrovich, CEO of the Alfred Mann Foundation (AMF) recently signed a milestone agreement that allows Ossur to further develop and license AMF's implanted myoelectric sensor (IM...

2019-11-04 15:37 2496

Picosun Expands Selection of Biocompatible ALD Materials for Medical Applications

ESPOO, Finland, Nov. 4, 2019 /PRNewswire/ -- Picosun Group, the leading supplier of AGILE ALD® (Atomic Layer Deposition) thin film coating solutions for global industries, expands its selection of biocompatible ALD materials to be used in medical applications. Picosun's TiO2 and Al2O3 processes ...

2019-11-04 13:00 364

Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

* Oligomannate, A New Oral Treatment For Mild To Moderate Alzheimer's Disease * The Only Approved Novel AD Treatment Globally Since 2003 SHANGHAI, Nov. 4, 2019 /PRNewswire/ -- Shanghai Green Valley Pharmaceuticals (Green Valley) today announced thatChina's National Medical Products Administrat...

2019-11-04 10:30 532

Healthcare Support Remains Strong For Singaporeans With Advanced Breast Cancer, But Patients Call For Greater Disease Education, Survey Finds

* The survey aims to better understand the lives of women living with advanced breast cancer and seeks to provide support to these women around the globe.[1] * With new and better treatments, patients with advanced breast cancer are now living longer and better than before SINGAPORE, Nov. 4, ...

2019-11-04 08:15 466

ClinicAll Enters Cooperation Partnership With The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group

NEW YORK, Nov. 3, 2019 /PRNewswire/ -- ClinicAll International Corporation is excited to announce the strategic partnership withThe Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group. New partnership between T...

2019-11-03 19:30 790

Medical Tourism Conference Enjoys Record Success after Relocation to Abu Dhabi

PALM BEACH GARDENS, Florida, Nov. 1, 2019 /PRNewswire/ --The Medical Tourism Association has successfully hosted its 12th World Medical Tourism & Global Healthcare Congress (WMTC) inAbu Dhabi since moving the event overseas for the first time. This year's 12th annual WMTC, took place from Oct....

2019-11-01 23:38 1143

Encore Medical Education Will Publish the Official Best of SABCS(R) News From the 2019 San Antonio Breast Cancer Symposium (SABCS(R)) Starting December 12, 2019

SAN ANTONIO, Texas, Nov. 1, 2019 /PRNewswire/ -- Encore Medical Education ( ) will publish the Official SABCS® News highlighting the key findings presented at the 42nd San Antonio Breast Cancer Symposium (SABCS®), held on December 10-14, 2019 in San...

2019-11-01 23:00 1153

High Performance Swine Production With Reduced Use of Antibiotics: Second Workshop by EW Nutrition and OPP Group

From 4 to 7 November, in Lleida, Spain, OPP Group and EW Nutrition are hosting their second workshop on animal health and welfare with reduced antibiotic use LLEIDA, Spain, Nov. 1, 2019 /PRNewswire/ -- The two-day event offers swine producers and other stakeholders essential, actionable informati...

2019-11-01 20:22 1128

Seneca Biopharma and Jiangsu QYuns Therapeutics Announce Development Plan for Potential Joint Pipeline at 7th China Renaissance Healthcare and Life Science Leadership Summit

GERMANTOWN, Maryland, Nov. 1, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (NASDAQ: SCNA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, and Jiangsu QYuns Therapeutics Co., Ltd., aChina-based company focused on monoclonal antibody thera...

2019-11-01 19:00 593

Dachser Air & Sea Logistics certified for pharmaceutical shipments on three continents

KEMPTEN, Germany, Nov. 1, 2019 /PRNewswire/ -- Following Frankfurt, Mumbai, and Hyderabad, Atlanta is now Dachser's fourth location to receive certification in ten months, further expanding the company's network services for its customers in the life science and healthcare sector.

2019-11-01 09:00 645

Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX®  (methoxsalen) has received regulatory approval inAustralia by th...

2019-11-01 04:35 5536

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

GERMANTOWN, Maryland, Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will begin trading on the Nasdaq Capital Market under the ticker symbol, NASDAQ: SNCA beginning onN...

2019-10-31 23:00 4074
1234567 ... 356